Table 1.
Demographics at core baseline of patients who received at least one deferasirox dose in the extension study
| Baseline LIC <7 mg Fe/g dw (n = 22) | Baseline LIC ≥7 mg Fe/g dw (n = 209) | |
|---|---|---|
| Mean age ± SD, yr | 9.4 ± 4.3 | 13.4 ± 7.1 |
| Patients aged 2 to <16 yr, n (%) | 20 (90.9) | 142 (67.9) |
| Patients aged ≥16 yr, n (%) | 2 (9.1) | 67 (32.1) |
| Female/male, n | 9 : 13 | 105 : 104 |
| History of hepatitis B and/or C, n (%) | 2 (9.1) | 69 (33.0) |
| Splenectomy, n (%) | 4 (18.2) | 89 (42.6) |
| Previous chelation therapy, n (%) | ||
| DFO monotherapy | 20 (90.9) | 164 (78.5) |
| Deferiprone monotherapy | 0 | 4 (1.9) |
| DFO + deferiprone | 2 (9.1) | 41 (19.6) |
| Median duration of previous chelation therapy (range), yr1 | 6.0 (0.3–15.6) | 6.7 (0.1–21.0) |
| Mean number of transfusion sessions in the year prior to study entry ± SD | 15.2 ± 3.1 | 15.1 ± 4.4 |
| Mean amount transfused in the year prior to study entry ± SD, mL/kg | 165 ± 42 | 173 ± 70 |
| Mean baseline LIC ± SD, mg Fe/g dw | 4.5 ± 1.8 | 21.1 ± 8.22 |
| Median baseline serum ferritin (range), ng/mL | 1921 (914–5696) | 3621 (998–25 008)2 |
1
Patients with LIC <7 mg Fe/g dw n = 16, patients with LIC ≥7 mg Fe/g dw n = 154.
2
n = 211.
SD, standard deviation; DFO, deferoxamine; LIC, liver iron concentrations.